Strides Pharma Science Limited considered and approved offering for subscription, on a private placement basis, up to 1,500 senior, secured, rated, unlisted, redeemable, Non-Convertible Debentures (NCDs) of face value INR 10,00,000 each aggregating up to INR 1500 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
876.7 INR | -0.76% | +3.94% | +35.03% |
Apr. 09 | Strides Pharma Science Gets US FDA Nod for Fluoxetine Tabs | MT |
Jan. 30 | Transcript : Strides Pharma Science Limited, Q3 2024 Earnings Call, Jan 30, 2024 |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+35.03% | 966M | |
+19.62% | 43.34B | |
+20.44% | 21.96B | |
+10.86% | 14.09B | |
+13.07% | 13.64B | |
+37.46% | 11.43B | |
-8.59% | 6.86B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+8.46% | 5.22B |
- Stock Market
- Equities
- STAR Stock
- News Strides Pharma Science Limited
- Strides Pharma Science Limited Approves Offering for Subscription Up to 1,500 Senior, Secured, Rated, Unlisted, Redeemable, Non-Convertible Debentures